

Linda Hammerich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7447679/publications.pdf>

Version: 2024-02-01

26
papers

1,202
citations

687220

13
h-index

752573

20
g-index

26
all docs

26
docs citations

26
times ranked

2408
citing authors

#	ARTICLE	IF	CITATIONS
1	Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. <i>Nature Medicine</i> , 2019, 25, 814-824.	15.2	293
2	Chemokine Receptor CXCR6-Dependent Hepatic NK T Cell Accumulation Promotes Inflammation and Liver Fibrosis. <i>Journal of Immunology</i> , 2013, 190, 5226-5236.	0.4	219
3	Role of IL-17 and Th17 Cells in Liver Diseases. <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-12.	3.3	202
4	Interleukins in chronic liver disease: lessons learned from experimental mouse models. <i>Clinical and Experimental Gastroenterology</i> , 2014, 7, 297.	1.0	99
5	<i>In situ</i> vaccination for the treatment of cancer. <i>Immunotherapy</i> , 2016, 8, 315-330.	1.0	71
6	Dendritic Cell and T Cell Crosstalk in Liver Fibrogenesis and Hepatocarcinogenesis: Implications for Prevention and Therapy of Liver Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7378.	1.8	62
7	Role of gamma-delta T cells in liver inflammation and fibrosis. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2014, 5, 107.	0.5	61
8	Emerging roles of myeloid derived suppressor cells in hepatic inflammation and fibrosis. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2015, 6, 43.	0.5	41
9	Lymphoma: Immune Evasion Strategies. <i>Cancers</i> , 2015, 7, 736-762.	1.7	35
10	Combination of G-CSF and a TLR4 inhibitor reduce inflammation and promote regeneration in a mouse model of ACLF. <i>Journal of Hepatology</i> , 2022, 77, 1325-1338.	1.8	31
11	In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 650486.	2.2	26
12	Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions. <i>Neuroendocrinology</i> , 2021, 111, 217-236.	1.2	17
13	From Liver Cirrhosis to Cancer: The Role of Micro-RNAs in Hepatocarcinogenesis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1492.	1.8	16
14	Antitumor T-cell Homeostatic Activation Is Uncoupled from Homeostatic Inhibition by Checkpoint Blockade. <i>Cancer Discovery</i> , 2019, 9, 1520-1537.	7.7	12
15	The Role of miRNA in the Pathophysiology of Neuroendocrine Tumors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8569.	1.8	8
16	Ferroptosis in Cancer Immunotherapy—Implications for Hepatocellular Carcinoma. <i>Immuno</i> , 2022, 2, 185-217.	0.6	3
17	Elevated Flt3L Predicts Long-Term Survival in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. <i>Cancers</i> , 2021, 13, 4463.	1.7	2
18	Combining In Situ Vaccination with Immune Checkpoint Blockade Induces Long-Term Regression of Lymphoma Tumors. <i>Blood</i> , 2016, 128, 465-465.	0.6	2

#	ARTICLE	IF	CITATIONS
19	Natural pattern-recognition-receptor agonists as adjuvants for in situ vaccination lymphoma immunotherapy.. Journal of Clinical Oncology, 2018, 36, 123-123.	0.8	1
20	Eat more carrots? Dampening cell death in ethanol-induced liver fibrosis by β^2 -carotene. Hepatobiliary Surgery and Nutrition, 2013, 2, 248-51.	0.7	1
21	Natural Toll-like Receptor Agonists for in Situ Vaccination Lymphoma Immunotherapy. Blood, 2015, 126, 4002-4002.	0.6	0
22	Converting a tumor from checkpoint blockade-resistant to checkpoint blockade-sensitive: Immunotransplant for aggressive lymphoma.. Journal of Clinical Oncology, 2016, 34, e14538-e14538.	0.8	0
23	Natural pattern-recognition-receptor agonists in prophylactic vaccines for in situ vaccination of lymphoma.. Journal of Clinical Oncology, 2016, 34, e14516-e14516.	0.8	0
24	Flt3L-based in situ vaccination for the treatment of lymphoma.. Journal of Clinical Oncology, 2016, 34, e19040-e19040.	0.8	0
25	Improving efficacy of PD-1 blockade in unresponsive lymphoma tumors with in situ vaccination through induction of a highly efficient cross-presenting dendritic cell subset.. Journal of Clinical Oncology, 2018, 36, 76-76.	0.8	0
26	Immune Regulatory 1 Cells: A Novel and Potent Subset of Human T Regulatory Cells. Frontiers in Immunology, 2021, 12, 790775.	2.2	0